Evaluate the Efficacy, Safety and Pharmacokinetics of GSK1325760A in the Treatment of Pulmonary Arterial Hypertension
Status:
Completed
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the effect of GSK1325760A on improvement
in exercise capacity in subjects with pulmonary arterial hypertension (PAH).
The secondary objectives of this study are to evaluate administration of GSK1325760A on:
- The safety and tolerability
- Improvement of PAH
- The steady-state plasma pharmacokinetics of GSK1325760A